Likelihood of Approval and Phase Transition Success Rate Model – (Nivolumab + Relatlimab) in Metastatic Uveal Melanoma
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – (Nivolumab + Relatlimab) in Metastatic Uveal Melanoma report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


(Nivolumab + Relatlimab) in Metastatic Uveal Melanoma Drug Details:
Nivolumab and Relatlimab-rmbw (Opdualag) is a fixed-dose combination of two IgG4 kappa monoclonal antibodies (mAbs). It is formulated as solution, concentrate solution for intravenous route of administration. Opdualag is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.BMS-986213, a fixed dose combination of nivolumab and relatlimab is under development for the treatment of hepatocellular carcinoma, refractory solid tumors, non-small cell lung cancer (NSCLC), recurrent or refractory classical Hodgkin lymphoma and b-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL), peripheral t-cell lymphomas (PTCL) and primary mediastinal B-cell lymphoma, gastric cancer, adenocarcinoma of the gastroesophageal junction, metastatic hepatocellular carcinoma, metastatic uveal melanoma, merkel cell carcinoma, head and neck squamous cell carcinoma (HNSC) and cutaneous squamous cell carcinoma, metastatic renal cell carcinoma and metastatic colorectal cancer. The drug candidate is formulated as solution administered by intravenous route. It is a monoclonal antibody directed against lymphocyte activation gene 3 protein (LAG3) and programmed cell death protein 1 (PD1). It is developed based on ENHANZE (recombinant human hyaluronidase PH20 enzyme (rHuPH20) Technology.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – (Nivolumab + Relatlimab) LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports